Results 161 to 170 of about 13,963,189 (308)

Predictors of Treatment Failure and Second-Line Therapy Outcomes After Rezūm Therapy for Benign Prostatic Hyperplasia. [PDF]

Cureus
Alhabib M, Engert P, Soave A, Wagenlehner F, Friedrich M, Alghueiri K.   +5 more
europepmc   +1 more source

KDAC6 alters cell morphology and motility through positive and negative modulation of F‐actin distribution

FEBS Open Bio, EarlyView.
KDAC6 has been associated with cell motility and actin structures, but specific domain contributions are not established. The two catalytic domains have differential effects on motility and F‐actin regulation, affecting cortical F‐actin density, motility, stress fibers, and cell spreading.
Taylor V. Joseph, Andrea B. Pham, Kiara E. Bornes, Razan H. Hammad, Chelsea A. Rousseve‐Ross, Thomas M. Huckaba, Terry J. Watt, Tasha B. Toro   +7 more
wiley   +1 more source

American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP. [PDF]

Blood Adv
Cuker A, Terrell DR, Sowdagar H, Arnold DM, Audia S, Bussel JB, González-López TJ, Grace RF, Masias C, McCrae KR, Mitrovic M, Neunert C, Panch SR, Shah S, Shy B, VandeVelde J, Cines DB, Vesely SK.   +17 more
europepmc   +1 more source

Identification of (20R)‐protopanaxadiol from Panax ginseng as a novel anti‐SARS‐CoV‐2 compound

FEBS Open Bio, EarlyView.
We established a noninfectious BAC‐based SARS‐CoV‐2 replicon that enables antiviral screening under BSL‐2 conditions. Using this platform, we screened 373 food‐derived compounds and identified (20R)‐protopanaxadiol from Panax ginseng as a novel inhibitor of SARS‐CoV‐2 RNA replication, highlighting the value of safe replicon systems for antiviral ...
Midori Takeda, Natsue Maezono, Rina Uchikoshi, Nobuyuki Kato, Masanori Ikeda   +4 more
wiley   +1 more source

Second-Line Therapy Following Osimertinib in Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer at an Academic Medical Center. [PDF]

Cancer Rep (Hoboken)
Rafizadeh M, Bogdan S, Lee J, Garcia C, Saxena A, Zhou K, Parang B.   +6 more
europepmc   +1 more source

Using cell‐free RNA to identify B‐ and T‐cell clonality for diagnosis and monitoring of B‐ and T‐cell neoplasms

FEBS Open Bio, EarlyView.
Using peripheral blood for determining B‐cell or T‐cell clonality is more reliable when we use cell‐free RNA (cfRNA) because cells release blood significantly more RNA than DNA. Next‐generation sequencing (NGS) of cfRNA allows us to evaluate fragment cfRNA and evaluate clonality reliably without the need for prior determination of the specific dominant
Adam Albitar, Sally Agersborg, Ahmed Charifa, Pooja Phull, Noa Biran, David Vesole, Harsh Parmar, Andrew Pecora, Andrew Ip, Andre Goy, David Siegel, Maher Albitar   +11 more
wiley   +1 more source

An application of weighted support vector machines to individualized second-line therapy selection after levodopa in Parkinson's disease. [PDF]

Front Hum Neurosci
Pham CT, Schneider RB, Venuto CS, Smith G, Brehm ZP, McDermott MP, Ertefaie A.   +6 more
europepmc   +1 more source

Second-line-Therapie mit Cabazitaxel [PDF]

best practice onkologie, 2010
openaire   +1 more source

Cell surface CD11c as a neutrophil aging marker molecule

FEBS Open Bio, EarlyView.
Cell surface CD11chi neutrophils were more aged and had better phagocytic function than CD11c−/lo neutrophils. Transcriptomic analysis of CD11chi neutrophils and CD11c−/lo neutrophils in pediatric population showed that the most difference was seen in infants.
Sophia Koutsogiannaki, Fahd Alhamdan, Erik Malm, Marie Bermudez, Samuel Y. Kim, Koichi Yuki   +5 more
wiley   +1 more source

A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma. [PDF]

Clin Cancer Res
Chon HJ, Heo J, Kim DY, Lim HY, Macarulla T, Gomez Martín C, Moreno V, Reig M, Ryu MH, Yoon JH, Baumann P, Bhoi S, Jensen M, Tunblad K, Wallberg H, Öberg F, Evans TRJ.   +16 more
europepmc   +1 more source